ERBB2 and breast cancer: To a lesser extent, the signature also predicted better clinical outcomes for OS (HR = 0.49 (0.28–0.86), logrank P = 0.01), RFS (HR = 0.57 (0.41–0.8), logrank P = 0.0009), and DMFS (HR = 0.63 (0.39–1.02), logrank P = 0.06) in HER2+ breast cancer patients (Figure 8, second panel).